| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sorbitan monooleate does not have a defined biological target as a therapeutic agent. It is a non-ionic surfactant and emulsifier used in cosmetics, pharmaceuticals, and food products. The compound is not intended to exert pharmacological effects. Its utility lies in its physical properties as an emulsifier and surfactant.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Sorbitan monooleate as a pharmacological agent are not documented in the literature. It is primarily used as an emulsifier and surfactant. The compound is not characterized for direct biological activities such as enzyme inhibition or receptor modulation. Its effects in biological systems are primarily related to its physical properties as a surfactant.
|
| ln Vivo |
Sorbitan monooleate is not used for in vivo pharmacological activity assessment as a drug compound. It is an emulsifier used in cosmetics, pharmaceuticals, and food products. The compound is not intended to be administered for therapeutic purposes. Its safety has been evaluated in the context of its use as a food additive and cosmetic ingredient.
|
| Enzyme Assay |
Sorbitan monooleate is not typically used in enzyme/receptor binding assays as a test compound. Its primary applications are as an emulsifier and surfactant. When used in research, it may be employed in studies of emulsion stability or as a component of formulations. Standard chemical and pharmaceutical protocols are employed for its use.
|
| Cell Assay |
Sorbitan monooleate is not used in cell-based assays as a test compound. Its primary applications are as an emulsifier and surfactant. The compound is not characterized for direct cellular effects. It may be used in studies of cell membrane interactions or as a component of formulations, but it is not a pharmacological agent.
|
| Animal Protocol |
Sorbitan monooleate is not used in animal studies as a pharmacological agent. Its primary applications are as an emulsifier in cosmetics, pharmaceuticals, and food products. The compound may be present in animal studies as a component of formulations or diets. Its safety has been established through its use in approved products.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
During digestion, both fatty acids and polyol sorbitol esters are absorbed, but the latter is completely excreted in the urine. /Sorbitol Monostearate/ Sorbitan monooleate has a molecular formula of C₂₄H₄₄O₆ and a molecular weight of 428.60 g/mol. It is a sorbitan ester of oleic acid, belonging to the Span series of surfactants. The compound is also known as Siben80 and is used as an emulsifier in cosmetics, pharmaceuticals, and food products. It is typically stored under standard laboratory conditions. |
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org Sorbitan monooleate is generally recognized as safe (GRAS) for use in food and cosmetic products when used in accordance with established guidelines. It is not intended for human therapeutic use as a drug substance. As a research chemical, standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. |
| References | |
| Additional Infomation |
Sorbitol monooleate is a fatty acid ester.
Sorbitan monooleate (Siben80) (CAS#: 1338-43-8) is a non-ionic surfactant and emulsifier belonging to the Span series. It is a sorbitan ester of oleic acid used as an emulsifier in cosmetics, pharmaceuticals, and food products. This compound is not a drug and is an emulsifier. |
| Molecular Formula |
C24H44O6
|
|---|---|
| Molecular Weight |
428.6026
|
| Exact Mass |
428.313
|
| CAS # |
1338-43-8
|
| PubChem CID |
9920342
|
| Appearance |
AMBER LIQUID
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
579.3±50.0 °C at 760 mmHg
|
| Melting Point |
0.986ºC
|
| Flash Point |
186.2±23.6 °C
|
| Vapour Pressure |
0.0±3.6 mmHg at 25°C
|
| Index of Refraction |
1.506
|
| LogP |
7.14
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
30
|
| Complexity |
453
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C([H])([H])[C@@]([H])([C@]([H])([C@@]1([H])[C@@]([H])(C([H])([H])OC(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)O[H])O[H])O[H]
|
| InChi Key |
NWGKJDSIEKMTRX-AAZCQSIUSA-N
|
| InChi Code |
InChI=1S/C24H44O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-22(27)29-19-21(26)24-23(28)20(25)18-30-24/h9-10,20-21,23-26,28H,2-8,11-19H2,1H3/b10-9-/t20-,21+,23+,24+/m0/s1
|
| Chemical Name |
[(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (Z)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3332 mL | 11.6659 mL | 23.3318 mL | |
| 5 mM | 0.4666 mL | 2.3332 mL | 4.6664 mL | |
| 10 mM | 0.2333 mL | 1.1666 mL | 2.3332 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.